Par Pharmaceutical Upgraded
An analyst upgraded Par Pharmaceutical Cos. (PRX) after the generic drug maker licensed the rights to BioAlliance Pharma's thrush treatment Loramyc. The stock price gained $1.75 to close at $30.30.
posted by FC Market News at 2:50 PM
0 Comments:
Post a Comment
<< Home